Eli Lilly and Company $LLY Stock Position Raised by IFP Advisors Inc

Key Points

• IFP Advisors increased its Eli Lilly position by 11.4% in the second quarter, bringing its holdings to 20,352 shares valued at approximately $24.4 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly insiders sold 13,500 shares worth about $16.0 million over the past 90 days, including sales by two executive vice presidents under pre-arranged Rule 10b5-1 trading plans.
• The company reported strong quarterly results, with revenue up 47.7% year over year to $22.97 billion and EPS of $8.38, beating estimates. Analysts maintain a “Moderate Buy” consensus, with an average price target of $1,295.39.

IFP Advisors Inc raised its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 11.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,352 shares of the company's stock after purchasing an additional 2,078 shares during the quarter. IFP Advisors Inc's holdings in Eli Lilly and Company were worth $24,411,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of LLY. California State Teachers Retirement System raised its position in Eli Lilly and Company by 120,133.2% during the second quarter. California State Teachers Retirement System now owns 1,460,379,190 shares of the company's stock valued at $1,751,622,612,000 after buying an additional 1,459,164,568 shares during the period. BlackRock Inc. boosted its position in Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares during the period. State Street Corp boosted its position in Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company's stock worth $38,002,744,000 after acquiring an additional 635,358 shares during the period. Morgan Stanley grew its stake in Eli Lilly and Company by 2.7% during the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company's stock valued at $16,757,510,000 after acquiring an additional 407,166 shares in the last quarter. Finally, Capital World Investors grew its stake in Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company's stock valued at $16,154,619,000 after acquiring an additional 61,851 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Buying and Selling

In related news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s GLP-1 franchise is described as growing at nearly 50% annually, supporting the company’s recent rise above a $1 trillion market capitalization. Analysts and commentators continue to see attractive medium-term prospects from strong demand for obesity and diabetes treatments. Eli Lilly Stock Has Become a Trillion-Dollar Giant
• Positive Sentiment: Coverage highlights Lilly’s broadening pipeline, with profits from incretin drugs helping fund development of the next generation of medicines. The company is also expected to use GLP-1 proceeds to expand into women’s health, potentially creating additional long-term growth avenues. Eli Lilly’s pipeline in 2026
• Positive Sentiment: Reports that Lilly rationed some launches because demand exceeded supply underscore the commercial strength of its products, although they also highlight the importance of expanding manufacturing capacity. What Eli Lilly Was Telling You While It Rationed Its Own Launches
• Neutral Sentiment: Articles comparing Lilly with Nvidia and projecting the value of long-term investments remain favorable toward Lilly’s growth story, but they are opinion pieces and do not introduce a new near-term earnings catalyst. Got $10,000? Eli Lilly vs. Nvidia
• Negative Sentiment: Investors are increasingly focused on whether Lilly’s valuation already reflects much of its GLP-1 success. The recent pullback and concerns about competition, supply, pipeline execution and the difficulty of sustaining rapid growth may be limiting upside and weighing on the stock. Eli Lilly Stock Has Become a Trillion-Dollar Giant

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on LLY shares. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 7th. UBS Group set a $1,376.00 price objective on shares of Eli Lilly and Company in a research note on Friday, August 7th. Wolfe Research reiterated an "outperform" rating and issued a $1,350.00 target price on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Cantor Fitzgerald lifted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada boosted their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an "outperform" rating in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $1,295.39.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,122.74 on Friday. Eli Lilly and Company has a 1 year low of $712.05 and a 1 year high of $1,292.65. The firm's fifty day simple moving average is $1,185.52 and its 200 day simple moving average is $1,072.89. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $1.06 trillion, a PE ratio of 37.68, a PEG ratio of 1.39 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the previous year, the business earned $6.31 EPS. The business's revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 10th. Investors of record on Friday, August 14th were given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, August 14th. Eli Lilly and Company's payout ratio is currently 23.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company's products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.